Recent advances in scleroderma-associated pulmonary hypertension.

Author: Kristen Highland
Date Published: September-2014
Source: Current Opinion in Rheumatology

Purpose of review: This review summarizes recent advances in pulmonary hypertension, a leading cause of morbidity and mortality in scleroderma (SSc). Recent findings: Although WHO Group I pulmonary arterial hypertension (PAH) is the most common cause of pulmonary hypertension, all WHO Groups can occur. PAH is now a criterion for the diagnosis of SSc. Results of recent research have resulted in greater insight into the epidemiology of SSc-pulmonary hypertension with regard to prevalence, incidence and clinical risk factors.